James Murphy, MD
Ophthalmology · Hamden, CTNPI 1558653014
Payments from drug & device makers
Across 387 payments — averaging $456.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$72K
- Nova Eye, Inc.$35K
- Glaukos Corporation$22K
- Bausch & Lomb Americas Inc.$16K
- AbbVie$12K
- Rxsight Inc$5K
- plus $15K from 22 others
Across 1 payment — averaging $19,990 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$20K
What the payments were for
- Consulting fees$60,26734%
- Speaking & faculty fees$81,30346%
- Travel & lodging$18,03410%
- Food & beverage$16,5549%
- Gifts$2160%
- Other$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 69 | $71,987 |
| Nova Eye, Inc. | 8 | $34,550 |
| Glaukos Corporation | 17 | $21,791 |
| Bausch & Lomb Americas Inc. | 43 | $15,843 |
| AbbVie(2 entities) | 129 | $12,458 |
| Rxsight Inc | 24 | $4,824 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $4,211 |
| Carl Zeiss Meditec USA, Inc. | 11 | $3,467 |
| Alcon | 28 | $2,851 |
| Ivantis, Inc | 5 | $1,225 |
| Lensar, Inc. | 2 | $1,058 |
| Microsurgical Technology, Inc. | 2 | $918 |
| Aerie Pharmaceuticals, Inc. | 7 | $261 |
| Mallinckrodt Hospital Products Inc. | 5 | $231 |
| Carl Zeiss Meditec, Inc. | 2 | $207 |
| Rayner Intraocular Lenses Limited | 6 | $150 |
| Harrow Eye, LLC | 6 | $123 |
| Astellas Pharma US Inc | 3 | $98 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $38 |
| Tarsus Pharmaceuticals, Inc. | 1 | $36 |
| Sun Pharmaceutical Industries Inc. | 1 | $28 |
| Eyepoint US, Inc. | 1 | $23 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Beaver-visitec International, Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Tearlab Corp | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$68,712
- enVista MX60 IOL$23,832
- SION SURGICAL INSTRUMENT$17,391
- enVista Aspire IOL$8,715
- LUMIGAN$8,446
- iDose$7,905
- RXSIGHT CONTACT LENS$4,028
- RXSIGHT INJECTOR CARTRIDGE$4,028
- RXSIGHT INJECTOR HANDPIECE$4,028
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,028
- CIRRUS HD-OCT$3,174
- COMBIGAN$3,124
- IOLMaster 700$2,817
- OMNI$2,628
- LIGHT ADJUSTABLE LENS (LAL)$2,624
- Tecnis Symfony IOL$2,132
- Tecnis 1-piece IOL$1,790
- Tecnis 3-piece IOL$1,790
- Tecnis Symphony IOL$1,790
- Tecnis Symphony Toric IOL$1,790
How this compares
$176,487 in reported general payments places this provider in the 95th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 107 | $73,829 |
| VyzultaLatanoprostene Bunod | 35 | $17,518 |
| RhopressaNetarsudil Mesylate | 25 | $12,510 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $11,067 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 58 | $10,920 |
| Latanoprost | 372 | $4,667 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $3,677 |
| Brimonidine Tartrate | 38 | $3,515 |
| Prednisolone Acetate | 54 | $2,458 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 13 | $1,848 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 158 | $1,600 |
| Travoprost | 13 | $1,237 |
| Dorzolamide Hcl | 45 | $662 |
| Timolol Maleate | 53 | $477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $12,458 | $84,897136 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $15,843 | $17,51835 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $261 | $16,18736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Hamden
- James MartoneHamden$3K
- Matthew PaulDanbury$944K
- Amir CohenNew Haven$441K
- John HuangHartford$390K
- Anthony DanielsNew Haven$66K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Anish ShahNorwich$38K
- Alan SolinskyWest Hartford$35K
- Michael KovalFarmington$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.